Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
All nigella sativa studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchNigella SativaNigella Sativa (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symp. case, any symptom 34% Improvement Relative Risk Symp. case, fever 97% Symp. case, chest pain 66% Symp. case, loss of taste/.. 62% Symp. case, muscle ache 26% Symp. case, chills -6% Symp. case, cough 79% Symp. case, headache 76% Symp. case, vomiting 98% Nigella Sativa  Daneshfard et al.  Prophylaxis  RCT Is prophylaxis with nigella sativa + olea europaea oil beneficial for COVID-19? RCT 173 patients in Iran (June 2021 - May 2022) Fewer symptomatic cases with nigella sativa + olea europaea oil (p=0.0061) c19early.org Daneshfard et al., Phytotherapy Research, Jul 2023 Favors nigella sativa Favors control

Effect of Sinamaz nasal drop on asymptomatic family members of COVID 19 patients: An open-label randomized controlled trial

Daneshfard et al., Phytotherapy Research, doi:10.1002/ptr.7915, IRCT20210515051305N1
Jul 2023  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 173 family members of COVID-19 patients, showing lower incidence of COVID-19 symptoms with nasal drops containing nigella sativa oil and olea europaea oil. One drop in each nostril twice daily for 7 days.
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.
risk of symptomatic case, 34.1% lower, RR 0.66, p = 0.006, treatment 37 of 89 (41.6%), control 53 of 84 (63.1%), NNT 4.6, any symptom.
risk of symptomatic case, 97.3% lower, RR 0.03, p < 0.001, treatment 1 of 89 (1.1%), control 35 of 84 (41.7%), NNT 2.5, fever.
risk of symptomatic case, 65.7% lower, RR 0.34, p = 0.06, treatment 4 of 89 (4.5%), control 11 of 84 (13.1%), NNT 12, chest pain.
risk of symptomatic case, 62.2% lower, RR 0.38, p = 0.10, treatment 4 of 89 (4.5%), control 10 of 84 (11.9%), NNT 13, loss of taste/smell.
risk of symptomatic case, 26.0% lower, RR 0.74, p = 0.16, treatment 29 of 89 (32.6%), control 37 of 84 (44.0%), NNT 8.7, muscle ache.
risk of symptomatic case, 6.2% higher, RR 1.06, p = 1.00, treatment 9 of 89 (10.1%), control 8 of 84 (9.5%), chills.
risk of symptomatic case, 79.0% lower, RR 0.21, p = 0.001, treatment 4 of 89 (4.5%), control 18 of 84 (21.4%), NNT 5.9, cough.
risk of symptomatic case, 76.4% lower, RR 0.24, p < 0.001, treatment 5 of 89 (5.6%), control 20 of 84 (23.8%), NNT 5.5, headache.
risk of symptomatic case, 98.1% lower, RR 0.02, p < 0.001, treatment 0 of 89 (0.0%), control 25 of 84 (29.8%), NNT 3.4, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), vomiting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Daneshfard et al., 16 Jul 2023, Randomized Controlled Trial, Iran, peer-reviewed, mean age 39.5 (treatment) 34.0 (control), 16 authors, study period 16 June, 2021 - 22 May, 2022, this trial uses multiple treatments in the treatment arm (combined with olea europaea oil) - results of individual treatments may vary, trial IRCT20210515051305N1.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperNigella SativaAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit